Investment Advisors

Raghuram Selvaraju, MBA '05

Senior Equity Research Analyst, Aegis Capital Corp.

Raghuram Selvaraju, Ph.D. MBA, is currently a Managing Director and Head of Healthcare Equity Research at Aegis Capital Corp., a full-service investment bank headquartered in New York City. He was previously a Senior Vice President and Senior Biotechnology Analyst at Morgan Joseph TriArtisan LLC, an investment bank with a private equity arm, and a senior equity research analyst covering the biotechnology and pharmaceuticals sectors at Noble Financial Group, Inc., also in New York City. He has 15 years' experience in the biotechnology and pharmaceutical industries, having started his career at the Serono Pharmaceutical Research Institute in Geneva, Switzerland ? the applied research arm of Serono, then Europe's largest biopharmaceutical firm ? as a pharmaceutical researcher. He began his sell-side research analyst career at Rodman & Renshaw in 2005 and subsequently was senior vice president and head of healthcare equity research at Hapoalim Securities, the New York-based broker/dealer subsidiary of Bank Hapoalim B.M., Israel's largest financial services group, covering biotechnology, specialty pharmaceuticals, molecular analytics, and diagnostics.

Dr. Selvaraju is widely quoted in national publications such as Barron's and The Wall Street Journal, as well as healthcare industry publications such as The Pink Sheet, BioWorld Today, and BioCentury, and has also been a frequent guest on Bloomberg TV and CNBC. He graduated from Carnegie-Mellon University in 1999 with a Bachelor of Science in Biological Sciences and Technical Writing, and received a Doctorate in Cell Biology and Neuroscience from the University of Geneva in 2004 and an M.B.A. from Cornell University's accelerated one-year program for scientists and engineers in 2005. Dr. Selvaraju has also published articles in leading peer-reviewed journals, presented research at various international scientific conferences, and is a co-inventor on several drug development patents.